MARKET

KZIA

KZIA

Kazia Therapeuti
NASDAQ
5.79
+0.17
+3.02%
After Hours: 5.79 0 0.00% 18:58 02/06 EST
OPEN
5.94
PREV CLOSE
5.62
HIGH
6.11
LOW
5.71
VOLUME
102.40K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
2.860
MARKET CAP
62.14M
P/E (TTM)
-0.4665
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KZIA last week (0126-0130)?
Weekly Report · 6d ago
Kazia Therapeutics Announces Preclinical And Translational Data Supporting Development Of NDL2 To Selectively Eliminate Nuclear PD-L1
Benzinga · 01/30 13:05
Kazia Therapeutics’ NDL2 shows anti-tumor efficacy in preclinical data
TipRanks · 01/30 13:05
KAZIA THERAPEUTICS LTD - NDL2 SHOWS REVERSAL OF IMMUNE EXHAUSTION AND ENHANCED ANTI-TUMOR ACTIVITY
Reuters · 01/30 13:01
KAZIA THERAPEUTICS LTD - PLANS FIRST-IN-HUMAN CLINICAL TRIALS FOR NDL2 IN 2027
Reuters · 01/30 13:01
Kazia Therapeutics Unveils Promising Preclinical Data for Nuclear PD-L1 Degrader
Reuters · 01/30 13:01
Analysts Conflicted on These Healthcare Names: Korro Bio (KRRO), Kazia Therapeutics (KZIA) and AbbVie (ABBV)
TipRanks · 01/28 14:20
Kazia Therapeutics Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 01/28 13:47
More
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Webull offers Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ: KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.